Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle
نویسندگان
چکیده
Traditionally, anti-platelet autoantibodies accelerating platelet clearance from the peripheral circulation have been recognized as the primary pathopysiological mechanism in chronic immune thrombocytopenia (ITP). Recently, increasing evidence supports the co-existence of insufficient megakaryopoiesis. Inadequate low thrombopoietin (TPO) levels are associated with insufficient proliferation and differentiation of megakaryocytes, decreased proplatelet formation, and subsequent platelet release. Recently two novel activators of TPO receptors have been made available: romiplostim and eltrombopag. In several phase III studies, both agents demonstrated increase of platelet counts in about 80% of chronic ITP patients within 2 to 3 weeks. These agents substantially broaden the therapeutic options for patients with chronic ITP although long-term results are still pending. This review will provide an update on the current conception of underlying mechanisms in ITP and novel, pathophysiologically based treatment options.
منابع مشابه
A Study of Epidemiology and Therapeutic Response of Patients with Immune Thrombocytopenic Purpura
Background: Immune thrombocytopenic purpura (ITP) is a disease characterized by decrease of the peripheral blood platelet count. The disease presents in acute and chronic forms. Because of the importance and high prevalence of ITP, it was decided to study the therapeutic response of patients with ITP. Material and Methods: A cross-sectional study was conducted at Ghaem hospital, Mashhad, Ira...
متن کاملGroningen Studies on megakaryopoiesis in patients with myelodysplasia and idiopathic thrombocytopenic purpura
متن کامل
Acute Immune Thrombocytopenic Purpura in Infants
Abstract Objective Immune thrombocytopenic purpura (ITP) manifests as an easy bruising or extravasation of blood from capillaries into skin and mucous membranes. The characteristics of acute ITP in infants have rarely been described. In order to better understand acute ITP in infants, the characteristics of the disease at this age group was investigated. Material and Methods The present des...
متن کاملClinical Features and Treatment Outcomes of 132 Infants with Immune Thrombocytopenic Purpura
Introduction: To determine common clinical symptoms, admission length, and treatment outcomes of infants with Immune Thrombocytopenic Purpura. Method: analysis of 132 infants with Immune Thrombocytopenic Purpura admitted to the emergency and hematology ward of Dr. Sheikh Hospital, with reference to age, gender, immunization history (preceding six weeks), presenting clinical features, treatment...
متن کاملClinical Features and Treatment Outcomes of Primary Immune Thrombocytopenic Purpura in Hospitalized Children Under 2-Years Old
Abstract Background Immune thrombocytopenic purpura (ITP) is the most prevalent cause of thrombocytopenia in children. Despite the importance of ITP in children under 2- years old, only a few publications are available in the literature. ITP usually presents itself as isolated thrombocytopenia and mucocutaneous bleeding. Materials and Methods T...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 4 شماره
صفحات -
تاریخ انتشار 2010